Strategic alliance between Hanil Pharm and BMS Korea hit snag

Published: 2003-10-10 06:59:00

Updated: 2003-10-10 06:59:00

Hanil Pharm said on October 7 that it has discontinued the ongoing strategic negotiation with the U.S.-based BMS Korea due to some different terms and conditions existing between both parties, adding that the final decision is likely to be made available after the meeting next week.

So far, BM...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK